| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.9 |